Abstract: Novel compounds of the formula I in which R is X is O or S, and R1, R2, R3, R4, R5 and R6 have the meaning indicated in patent claim 1, or a tautomeric ring-closed form, and the (E) isomers and their salts exhibit endothelin receptor-antagonistic properties.

Abstract: A growth hormone secretagogue is useful for enhancing the return of patients to independent living status following acute deconditioning such as that which may result from immobilization, surgery, or major injury such as hip fracture.

Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.

Abstract: A microcarrier based process to produce viral vaccines, of which one example is hepatitis A virus (HAV), is composed of an aggregated microcarrier system of glass coated polystyrene microcarriers and MRC-5 cells which creates a stable environment for the propagation of the virus over even extended infection periods. The microcarrier aggregates formed according to this process eliminate the sloughing of cells from the beads during long cultivations seen in other systems, allowing high virus productivity in microcarrier culture. The methodology is applicable where virus production can be enhanced by creating a stable culture during an extended infection period. Scalable stirred bioreactors are used instead of multiple parallel stationary surface bioreactors.

Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.

Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.

Abstract: The invention describes an improved process for synthesizing 1-&bgr;-methyl-2-hydroxymethyl substituted carbapenems as key intermediates for the synthesis of anti-MRSA carbapenem antibiotics. The synthesis eliminates the use of BU3SnCH2OH and HMPA, which are toxic substances and not amenable to industrial scale production. The novel intermediates are also within the scope of this invention. The invention relates to the synthesis of a compound of formula 3: wherein R1 represents H or a suitable protecting group for an alcohol; R2 represents H or methyl; and R5 represents a carboxy protecting group as well as the compounds made therein.

Abstract: The present invention describes an improved process for the preparation, isolation, and purification of the anti-ulcer agent omeprazole whereby the sulfide precursor pyrmetazole is reacted subsurfacely with exactly one molar equivalent of meta-chloroperoxybenzoic acid in a chlorinated aliphatic hydrocarbon or aromatic hydrocarbon solvent, such as methylene chloride or toluene; residual organic solvent is removed from the aqueous layer by vacuum distillation; crude product is obtained by reactive crystallization with an alkyl formate or formic acid solution and seeding; and pure product is isolated by recrystallization in methanol-water containing aqueous NaOH by subsurface addition of aqueous acetic acid to pH 9.0, seeding, filtration, washing, and drying. Omeprazole and compositions of omeprazole containing no chromatographically detectable levels of residual non-alcoholic organic reaction solvent and diminished levels of alcoholic solvent are also described.

Abstract: Compounds of the general structural formula I are selective NPY Y5 receptor antagonists. The compounds and compositions of the present invention are useful in the treatment of obesity and complications associated therewith.

Abstract: The present invention is directed to the development of a highly safe high-chroma orange pearl pigment replacing a cadmium pigment, in which a flaky substrate has surfaces coated with spherical metal oxide particles containing iron oxide, or spherical metal oxide particles obtained by adding thereto a specific proportion of one or more oxides selected from among aluminum, calcium and magnesium oxides, and a process for manufacturing the same, and uses thereof.

Abstract: para-Aminomethylaryl carboxamides of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

Abstract: An electroptical system which between 2 electrode layers contains a PDLC film comprising a liquid crystal mixture forming micro-droplets in an optically isotropic, transparent polymer matrix, in which one of the refractive indices of the liquid crystal mixture is matched to the refractive index of the polymer matrix, which exhibits an electrically switchable transparency essentially independent of the polarization of the incident light, the precursor of the PDLC film of which comprises one or more monomers, oligomers and/or prepolymers and a photoinitiator, and is cured photoradically, the liquid crystal mixture of which comprises one or more compounds of the formula I in which the substituents are defined herein characterized in that the liquid crystal mixture additionally contains one or more reactive liquid crystalline compounds in order to obtain improved switching times especially at low temperatures.

Abstract: The present invention relates to a transgenic nonhuman animal lacking native amyloid precursor protein. The transgenic mouse of the invention may be used in the study of Alzheimer's Disease and disorders involving the central nervous system.

Abstract: The invention relates to novel light protection filters for the VIS and IR region for the preparation of sunscreens and also to the use thereof in cosmetics. The invention further relates to sunscreens which have broad-band or ultraspectral protection.

Abstract: Three classes of indole and indoline derivatives are disclosed as ligands selective for the 5-HT6 receptors, and hence of value in the treatment or prevention of CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression and anxiety. A particular class, 1-substituted-4-(&ohgr;-N,N-dialkyl-aminoalkyl)indoles, are claimed as novel compounds.

Abstract: The novel process of this invention involves the stereoselective synthesis of certain 16-substituted 4-aza-5&agr;-androst-1-en-3-ones, and the useful intermediates obtained therein.

Abstract: Antiviral and antifungal compositions comprising a mixture of a ferrous salt and an aqueous plant extract of pomegranate rind, Viburnum plicatum leaves or flowers, tea leaves or maple leaves are disclosed.

Abstract: The invention relates to polymerizable fluorophenylenes of formula I wherein P, Sp, X, n, L, Z1, Z2, A, B, m and R have the meaning of claim 1, to a polymerizable liquid crystalline composition comprising at least one polymerizable mesogenic fluorophenylene of formula I, to the use of the inventive mesogenic fluorophenylenes and compositions comprising them for the preparation of linear or crosslinked liquid crystalline polymers, and to the use of inventive compounds, compositions and polymers in liquid crystal displays, polarizers, compensators, alignment layers, color filters or holographic elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics, liquid crystal pigments, for decorative and security applications, in nonlinear optics, optical information storage or as chiral dopants.

Abstract: Supertwist liquid-crystal displays (SLCDs) with outstanding properties are obtained if the nematic liquid-crystal mixtures used therein comprise one or more compounds of the formula IA and one or more compounds of the formula IB Ra is alkyl, alkoxy, alkenyl or alkenyloxy having 1 to 12 carbon atoms, Rb is alkyl or alkoxy having 1 to 5 carbon atoms, Z is —COO —CH2CH2— or a single bond, and  are each, independently of one another,  and one of the rings  may alternatively be R3 is an alkenyl group having 2 to 7 carbon atoms, R4 is as defined for Ra in the formula IA, and c is 0 or 1.

Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.